Comparison of S-1 Plus Oxaliplatin by Arterial Infusion and SOX Regimens for Locally Advanced Gastric Cancer

• Status: Not yet recruiting
• Trial end date: 2026-12-01

Summary

SOX regimen, consisting of oral S-1 and intravenous oxaliplatin, is the preferred regimen for perioperative chemotherapy for gastric cancer. The goal of this clinical trial is to compare the efficacy and safety between S-1 combined with oxaliplatin by arterial infusion, as neoadjuvant chemotherapy, and conventional SOX regimen, in locally advanced gastric cancer. The main question it aims to answer is: whether arterially infused oxaliplatin plus S-1 has the potential to be a better neoadjuvant option for patients with locally advanced gastric cancer.

Participants will be randomised, and receive:

• 3 cycles of conventional SOX chemotherapy or arterial infused oxaliplatin plus S-1, as neoadjuvant chemotherapy;

• Adequate gastric resection along with D2 lymph node dissection;

• 5 cycles adjuvant chemotherapy using SOX regimen.

Researchers will compare the 2-year overall survival (OS) rates, 2-year disease free survival (DFS), R0 resection rates, and adverse events, to see if the modified perioperative chemotherapy improve the prognosis of patients with locally advanced gastric cancer.

• Phase: Phase 3

Details

• Lead Sponsor: Zhejiang University
• Treatments: Oxaliplatin